Related Experiment Video

Updated: Jun 3, 2025

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.0K

Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes

Pablo Corral1, Natalia Nardelli2, Alicia Elbert3

  • 1Facultad de Medicina, Departamento de Farmacología e Investigación, Universidad FASTA, Instituto de Investigaciones Clínicas (IIC), Mar del Plata, Argentina. drpablocorral@gmail.com.

Current Diabetes Reports
|January 6, 2025
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer cardiovascular benefits for type 2 diabetes mellitus (T2DM) patients. While effects on LDL cholesterol vary, SGLT2i improve triglycerides and HDL-C, potentially reducing cardiovascular risk.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is associated with increased cardiovascular disease (CVD) risk.
  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are established glucose-lowering agents with proven CVD benefits.
  • Understanding SGLT2i's impact on lipid profiles is crucial for optimizing CVD risk management in T2DM.

Purpose of the Study:

  • To review the cardiovascular effects of SGLT2i in T2DM patients.
  • To specifically analyze the impact of SGLT2i on various lipid parameters.
  • To elucidate the role of lipoprotein changes in SGLT2i's cardiovascular benefits.

Main Methods:

  • Systematic review of clinical trials and observational studies.
  • Analysis of data on lipid profiles (LDL-C, HDL-C, triglycerides) and cardiovascular outcomes.
  • Exploration of potential mechanisms underlying lipid modulation by SGLT2i.

Main Results:

  • SGLT2i demonstrate significant cardiovascular benefits in T2DM, independent of glycemic control.
  • Effects on LDL cholesterol are inconsistent, with some studies showing modest increases.
  • Consistent findings include reductions in triglycerides and increases in HDL-C, alongside a shift towards less atherogenic lipid profiles (e.g., reduced small, dense LDL particles).

Conclusions:

  • SGLT2i represent a significant therapeutic advancement for T2DM patients, offering cardiovascular protection.
  • While LDL-C effects require further investigation, SGLT2i favorably modulate other lipid parameters, contributing to reduced CVD risk.
  • Further research is needed to fully elucidate the mechanisms of SGLT2i-induced lipid changes and their clinical implications.
Keywords:
Cardiovascular riskDyslipidemiaHDL cholesterolLDL cholesterolSGLT2 inhibitorsTriglyceridesType 2 diabetes mellitus

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

67.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
152
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
185
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
529